Develops drugs for liver cancer and SARS Coronavirus infections.
Jun 2026Revenue $35.3M/yrExpenses $41.2M/yr
No trend
Figures by year
When will Sunshine Biopharma be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $35.3M and expenses $41.2M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $36.3M | $42.5M | −$6.23M |
| Dec 2024 | $34.9M | $40.7M | −$5.81M |
| Dec 2023 | $24.1M | $28.9M | −$4.79M |
| Dec 2022 | $4.35M | $31.3M | −$27.0M |
| Dec 2021 | $228K | $2.67M | −$2.44M |
| Dec 2020 | $71.4K | $648K | −$577K |
| Dec 2019 | $21.1K | $663K | −$642K |
| Dec 2018 | $0.00 | $1.16M | −$1.16M |
| Dec 2017 | $0.00 | $857K | −$857K |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.